Literature DB >> 9139482

Adjuvants--a classification and review of their modes of action.

J C Cox1, A R Coulter.   

Abstract

Since early this century, various substances have been added to vaccines and certain formulations have been devised in an attempt to render vaccines more effective. Despite a plethora of options, only aluminium salts have gained acceptance as human vaccine adjuvants and even veterinary vaccines are largely dependent upon the use of aluminium salts. Currently, many new vaccines are under development and there is a desire to simplify vaccination schedules both by increasing the number of components per vaccine and decreasing the number of doses required for a vaccine course. New, more effective adjuvants will be required to achieve this.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9139482     DOI: 10.1016/s0264-410x(96)00183-1

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  105 in total

1.  Induction of a protective capsular polysaccharide antibody response to a multiepitope DNA vaccine encoding a peptide mimic of meningococcal serogroup C capsular polysaccharide.

Authors:  Deborah M Prinz; S Louise Smithson; Thomas Kieber-Emmons; M A Julie Westerink
Journal:  Immunology       Date:  2003-10       Impact factor: 7.397

Review 2.  The development and use of vaccine adjuvants.

Authors:  Robert Edelman
Journal:  Mol Biotechnol       Date:  2002-06       Impact factor: 2.695

Review 3.  Regulation of CD4 T-cell receptor diversity by vaccine adjuvants.

Authors:  Christina K Baumgartner; Laurent P Malherbe
Journal:  Immunology       Date:  2010-03-17       Impact factor: 7.397

4.  Antigen targeting to major histocompatibility complex class II with streptococcal mitogenic exotoxin Z-2 M1, a superantigen-based vaccine carrier.

Authors:  Fiona J Radcliff; Jacelyn M S Loh; Birgit Ha; Diana Schuhbauer; James McCluskey; John D Fraser
Journal:  Clin Vaccine Immunol       Date:  2012-02-01

Review 5.  Safety and tolerability evaluation of the use of Montanide ISA™51 as vaccine adjuvant: A systematic review.

Authors:  Eva van Doorn; Heng Liu; Anke Huckriede; Eelko Hak
Journal:  Hum Vaccin Immunother       Date:  2015-09-17       Impact factor: 3.452

6.  Therapeutic Chlamydophila abortus and C. pecorum vaccination transiently reduces bovine mastitis associated with Chlamydophila infection.

Authors:  Carolin Biesenkamp-Uhe; Yihang Li; Hans-Robert Hehnen; Konrad Sachse; Bernhard Kaltenboeck
Journal:  Infect Immun       Date:  2006-11-21       Impact factor: 3.441

7.  Immunogenicity of two Echinococcus granulosus antigens EgA31 and EgTrp in mice.

Authors:  M Fraize; M E Sarciron; S Azzouz; N Issaadi; G Bosquet; A F Petavy
Journal:  Parasitol Res       Date:  2005-04-12       Impact factor: 2.289

Review 8.  Vaccines: all things considered.

Authors:  Ken S Rosenthal; Daniel H Zimmerman
Journal:  Clin Vaccine Immunol       Date:  2006-08

9.  Effect of a trivalent vaccine against Staphylococcus aureus mastitis lymphocyte subpopulations, antibody production, and neutrophil phagocytosis.

Authors:  Jai-Wei Lee; Celia N O'Brien; Albert J Guidry; Max J Paape; Kimberley A Shafer-Weaver; X Zhao
Journal:  Can J Vet Res       Date:  2005-01       Impact factor: 1.310

10.  Synthesis and characterization of antigenic influenza A M2e protein peptide-poly(acrylic) acid bioconjugate and determination of toxicity in vitro.

Authors:  Yasemin Budama Kilinc; Zeynep Mustafaeva Akdeste; Rabia Cakir Koc; Melahat Bagirova; Adil Allahverdiyev
Journal:  Bioengineered       Date:  2014-11-11       Impact factor: 3.269

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.